Prognostic relevance of primary tumor location in stage III and II colon cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 703-703
Author(s):  
Arantzazu Martínez Barquín García ◽  
Olga Martinez Saez ◽  
Juan José Serrano Domingo ◽  
Roberto Martín Huertas ◽  
Maria Villamayor Delgado ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factor ◽  
Primary Tumor ◽  
Cox Model ◽  
Tumor Location ◽  
Stage Ii ◽  
Stage Iii ◽  
Primary Tumor Location ◽  
Risk Of Death ◽  
Prognostic Relevance

703 Background: Primary tumor location of colon cancer (CC) is emerging as an important prognostic factor owing to distinct biological features. However, this factor still does not represent a prognostic parameter when deciding for adyuvant or palliative chemotherapy. In a meta-analysis of 66 studies including patients with all stages of disease, left-sided primary tumor location was associated with a significantly reduced risk of death and this was independent of other prognostic factors. Methods: We retrospectively included patients with stage II and III CC that underwent surgical resection between 2009 and 2014 HURyC. We performed a multivariate Cox model analysis to estimate if tumor location is an independent prognostic factor for overall survival (OS). The model was further adjusted by including the following confounders: ECOG-PS, number of removed nodes ( < 12 or ≥ 12), perforation, grade, use of adyuvant chemotherapy and age. A covariate was considered a confounder factor if the difference between the adjusted and unadjusted coefficient of chemotherapy varied > 10%. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (267 left sided and 297 right sided). The median follow-up of the entire cohort was 49 months. Globally, right sided CC was not significantly associated with better DFS or OS in comparison with left sided CC (HR: 0.74, p: 0.128; HR: 0.94, p: 0.75, respectively). By stages, stage II right sided CC seemed to show better DFS (HR: 0.45, p: 0.02), although no significant differences were found in OS (HR: 1.004, p: 0.98). Stage III right sided CC was not significantly associated with better DFS or OS in comparison with left sided CC (HR: 0.87, p: 0.585; HR: 0.66, p: 0.19, respectively). Conclusions: The multivariate analysis did not show significant differences in terms of prognostic relevance of primary tumor location in the adyuvant setting.

Impact of adyuvant chemotherapy treatment according to tumor primary location in colorectal cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 655-655
Author(s):  
Arantzazu Martínez Barquín García ◽  
Olga Martinez Saez ◽  
Elena Corral de la Fuente ◽  
Juan José Serrano Domingo ◽  
Roberto Martín Huertas ◽  
...  
Keyword(s):  
Primary Tumor ◽  
Cox Model ◽  
Multivariable Analysis ◽  
Tumor Location ◽  
Stage Ii ◽  
University Hospital ◽  
Stage Iii ◽  
Primary Tumor Location ◽  
Entire Cohort ◽  
The Difference

655 Background: Adyuvant chemotherapy is a unified therapeutic principle in colon cancer (CC). However, many prognostic factors are arising to determine who really benefits from adyuvant chemotherapy in order to avoid overtreatment. Primary tumor location of CC is emerging as an important prognostic factor owing to distinct biological features. However, there is hardly any evidence showing the benefit of treatment according to primary tumor location. Methods: We retrospectively included patients with stage II and III CC that underwent surgical resection between 2009 and 2014 HURyC. We performed a multivariable Cox model analysis to estimate the benefit of chemotherapy according to tumor location in terms of DFS and OS. The model was further adjusted by including the following confounders: ECOG-PS, number of removed nodes ( < 12 or ≥ 12), use of adyuvant chemotherapy and age. A covariate was considered a confounder factor if the difference between the adjusted and unadjusted coefficient of chemotherapy varied > 10%. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (267 left sided and 297 right sided). The median follow-up of the entire cohort was 49 months. Globally, chemotherapy did not improve DFS neither in right sided or left sided CC (HR: 0.81, p: 0.58; HR 1.31, p: 0.4, respectively). As for OS, it was improved when adding chemotherapy in both sides (right sided CC HR 0.51, p: 0.061 and left sided CC HR 0.42, p: 0.009). By stages, chemotherapy did not improve DFS or OS according to tumor localization in stage II. In right sided stage III, there was a trend to improve both DFS and OS (HR: 0.54, p: 0.14; HR: 0.39, p: 0.1, respectively). In left sided stage III, there was a trend to improve DFS (HR: 0.66, p: 0.36) and there was an improvement in OS (HR: 0.23, p < 0.001). Conclusions: The multivariable analysis showed benefit of chemotherapy in both right and left sided CC in terms of OS, exhibiting more benefit those patients with left sided CC.

Primary tumor location in stage III colon cancer has prognostic impact on subsequent liver metastasis

2018 ◽  
Vol 118 (8) ◽  
pp. 1301-1310 ◽  
Author(s):  
Chun‐Kai Liao ◽  
Jy‐Ming Chiang ◽  
Wen‐Sy Tsai ◽  
Jeng‐Fu You ◽  
Pao‐Shiu Hsieh ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Liver Metastasis ◽  
Primary Tumor ◽  
Tumor Location ◽  
Stage Iii ◽  
Prognostic Impact ◽  
Primary Tumor Location ◽  
Stage Iii Colon Cancer

scholarly journals Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status.

2017 ◽  
Vol 28 ◽  
pp. iii142 ◽  
Author(s):  
Julien Taieb ◽  
Raphael Kourie Hampig ◽  
François Emile Jean ◽  
Karine Le Malicot ◽  
Ralyath Balogoun ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Tumor Location ◽  
Stage Iii ◽  
Primary Tumor Location ◽  
Stage Iii Colon Cancer ◽  
Mutational Status

scholarly journals Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer WithRASandBRAFMutational Status

JAMA Oncology ◽  
2018 ◽  
Vol 4 (7) ◽  
pp. e173695 ◽  
Author(s):  
Julien Taieb ◽  
Hampig Raphael Kourie ◽  
Jean-François Emile ◽  
Karine Le Malicot ◽  
Ralyath Balogoun ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Tumor Location ◽  
Stage Iii ◽  
Primary Tumor Location ◽  
Stage Iii Colon Cancer

scholarly journals Relationship between primary tumor location and mortality in stage II colon cancer

2017 ◽  
Vol 28 ◽  
pp. x49
Author(s):  
S. Pinto-Torres ◽  
M. Malheiro ◽  
J. Rato ◽  
T. André ◽  
A. Gradil ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Primary Tumor ◽  
Tumor Location ◽  
Stage Ii ◽  
Primary Tumor Location ◽  
Stage Ii Colon Cancer

Benefit of adjuvant treatment in stages II and III colon cancer: Experience at the Ramón y Cajal University Hospital.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 842-842
Author(s):  
Olga Martinez Saez ◽  
Arantzazu Martínez Barquín García ◽  
Cristina Saavedra Serrano ◽  
Elena Corral de la Fuente ◽  
Juan José Serrano Domingo ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Treatment ◽  
Cox Model ◽  
Multivariable Analysis ◽  
Stage Ii ◽  
University Hospital ◽  
Stage Iii ◽  
Risk Of Death ◽  
Stage Iii Colon Cancer ◽  
Ramón Y Cajal

842 Background: The standard adjuvant treatment for patients with stage III colon cancer is 6 months with fluoropyrimidines and oxaliplatin. The Intergroup Trial INT-0035 was the first large-scale study to demonstrate a significant reduction in the risk of death with adjuvant FU plus levamisole in patients with stage III colon cancer. In the MOSAIC study, the addition of oxaliplatin to fluoropyrimidines in patients with resected stage II to III colon cancer showed OS and DFS benefit of oxaliplatin. However, no significant benefit was observed in either DFS or OS in patients with stage II disease, therefore the benefit of adjuvant chemotherapy is still controversial in those patients. Methods: We retrospectively included patients with stages II and III colon cancer that were operated between 2009 and 2014 in the University Ramón y Cajal Hospital from Madrid. We calculate DFS and OS at 48 months and we perform a multivariable Cox model analysis to estimate the benefit of the chemotherapy in each stage. The model was further adjusted by including the following confounders: ECOG-PS, number or removed nodes ( < 12 or ≥ 12), grade and age. A covariate was considered a confounder factor if the difference between the adjusted and unadjusted coefficient of chemotherapy varied > 10%. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (281 stage II and 283 stage III). 259 received chemotherapy and 305 did not. The median follow-up in the entire cohort was 49 months. The median DFS and OS were not reached at the moment of the analysis. DFS and OS at 48 months were both 78.5%. Globally, chemotherapy did not improve DFS (HR 1.05, p: 0.83) but OS was significantly better (HR 0.47, p: 0.001). By stage, chemotherapy did not improve DFS in stage II (HR: 1.6, p: 0.2) nor OS (HR 0.76, p: 0.43). In stage III, chemotherapy showed a trend to improve DSF (HR: 0.61, p: 0.075) and did improve OS (HR: 0.31, p < 0.0001). Conclusions: The multivariable analysis showed a chemotherapy benefit in patients with stage III colon cancer, with a 39% reduction in the risk of recurrence and a 69% in the risk of death; however, in stage II patients these benefits were not found either in DFS or OS.

scholarly journals Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (58) ◽  
pp. 99136-99149 ◽  
Author(s):  
Lin Yang ◽  
Wenzhuo He ◽  
Qiong Yang ◽  
Pengfei Kong ◽  
Qiankun Xie ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Mismatch Repair ◽  
Primary Tumor ◽  
Tumor Location ◽  
Stage Ii ◽  
Primary Tumor Location ◽  
Mismatch Repair Status ◽  
Stage Ii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document